Daré Bioscience Q3 revenue jumps on R&D services and product sales, net loss narrows

By Reuters News


Overview

  • US women's health biotech's Q3 revenue rose sharply yr/yr, driven by R&D services and product sales

  • Net loss narrowed compared to prior year

  • Company highlighted commercial progress for DARE to PLAY and Flora Sync LF5


Outlook

  • Company expects to begin recording revenue from DARE to PLAY Sildenafil Cream in Q4 2026

  • Company does not expect product revenue to be material during 2026

  • Revenue from DARE to RECLAIM intravaginal ring targeted to begin in 2027


Result Drivers

  • R&D SERVICES REVENUE - Q3 revenue increase was primarily due to research and development services under agreements with the Gates Foundation

  • FLORA SYNC LF5 SALES - Revenue from sales of Flora Sync LF5 began in July 2026, contributing to Q3 revenue

  • LOWER R&D EXPENSES - Decreased R&D expenses reflected lower costs for several development programs, including Sildenafil Cream, DARE-LARC1, and Ovaprene


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Loss Per Share

$0.18


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the pharmaceuticals peer group is "buy"

  • Wall Street's median 12-month price target for Dare Bioscience Inc is $8.00, about 1,116.9% above its November 13 closing price of $0.66


Reuters Recommended Reads

  • Nov 13 - Nutritional supplements maker Natural Alternatives' Q1 revenue falls on private-label sales drop

  • Nov 13 - Indaptus Therapeutics Q3 net loss narrows as R&D costs fall

  • Nov 16 - AstraZeneca gets US nod for expanded Imfinzi use, new rare-disease therapy


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.